Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSHT | ISIN: US92539P1012 | Ticker-Symbol:
NASDAQ
28.03.25
20:37 Uhr
5,160 US-Dollar
-0,205
-3,82 %
1-Jahres-Chart
VERVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VERVE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VERVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCanaccord maintains $32 target on Verve Therapeutics stock1
MoVerve Therapeutics gets FDA approval to begin cholesterol treatment trial2
MoVerve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose82BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its...
► Artikel lesen
05.03.Verve Therapeutics (NASDAQ:VERV) Shares Gap Down on Analyst Downgrade4
03.03.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)102BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28...
► Artikel lesen
VERVE THERAPEUTICS Aktie jetzt für 0€ handeln
27.02.Verve Therapeutics GAAP EPS of -$0.58 beats by $0.11, revenue of $13.08M beats by $8.84M3
27.02.Verve Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
27.02.Verve Therapeutics, Inc. - 10-K, Annual Report-
27.02.Verve Therapeutics, Inc. - 8-K, Current Report-
03.02.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)838BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025...
► Artikel lesen
03.01.Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)180BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,...
► Artikel lesen
29.12.24Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?11
29.11.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)255BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,...
► Artikel lesen
05.11.24Verve Therapeutics, Inc. - 10-Q, Quarterly Report8
05.11.24Verve Therapeutics, Inc. - 8-K, Current Report2
01.11.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)222BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024...
► Artikel lesen
02.10.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)260BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30...
► Artikel lesen
03.09.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)280BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024...
► Artikel lesen
02.08.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)334BOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024...
► Artikel lesen
01.07.24Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)239BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3